Outcomes of Facility-level Use of Ferumoxytol versus Other Intravenous Iron Formulations in Incident Hemodialysis Patients
Publication
, Conference
Airy, M; Mandayam, S; Mitani, AA; Chang, TI; Brookhart, MA; Goldstein, BA; Winkelmayer, WC
Published in: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
September 1, 2015
Duke Scholars
Published In
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
EISSN
1099-1557
ISSN
1053-8569
Publication Date
September 1, 2015
Volume
24
Start / End Page
341 / 342
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Pharmacology & Pharmacy
- 4202 Epidemiology
- 3214 Pharmacology and pharmaceutical sciences
- 1117 Public Health and Health Services
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Airy, M., Mandayam, S., Mitani, A. A., Chang, T. I., Brookhart, M. A., Goldstein, B. A., & Winkelmayer, W. C. (2015). Outcomes of Facility-level Use of Ferumoxytol versus Other Intravenous Iron Formulations in Incident Hemodialysis Patients. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (Vol. 24, pp. 341–342). WILEY-BLACKWELL.
Airy, Medha, Sreedhar Mandayam, Aya A. Mitani, Tara I. Chang, M Alan Brookhart, Benjamin A. Goldstein, and Wolfgang C. Winkelmayer. “Outcomes of Facility-level Use of Ferumoxytol versus Other Intravenous Iron Formulations in Incident Hemodialysis Patients.” In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 24:341–42. WILEY-BLACKWELL, 2015.
Airy M, Mandayam S, Mitani AA, Chang TI, Brookhart MA, Goldstein BA, et al. Outcomes of Facility-level Use of Ferumoxytol versus Other Intravenous Iron Formulations in Incident Hemodialysis Patients. In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. WILEY-BLACKWELL; 2015. p. 341–2.
Airy, Medha, et al. “Outcomes of Facility-level Use of Ferumoxytol versus Other Intravenous Iron Formulations in Incident Hemodialysis Patients.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 24, WILEY-BLACKWELL, 2015, pp. 341–42.
Airy M, Mandayam S, Mitani AA, Chang TI, Brookhart MA, Goldstein BA, Winkelmayer WC. Outcomes of Facility-level Use of Ferumoxytol versus Other Intravenous Iron Formulations in Incident Hemodialysis Patients. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. WILEY-BLACKWELL; 2015. p. 341–342.
Published In
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
EISSN
1099-1557
ISSN
1053-8569
Publication Date
September 1, 2015
Volume
24
Start / End Page
341 / 342
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Pharmacology & Pharmacy
- 4202 Epidemiology
- 3214 Pharmacology and pharmaceutical sciences
- 1117 Public Health and Health Services
- 1115 Pharmacology and Pharmaceutical Sciences